2026-04-17T14:50:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/657572025-12-04T22:29:31Zcom_2072_1057col_2072_478917col_2072_478931

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection  Ascher-Svanum, Haya Novick, Diego Haro Abad, Josep Maria Bertsch, Jordan McDonnell, David Detke, Holland Antipsicòtics Esquizofrènia Qualitat de vida Antipsychotic drugs Schizophrenia Quality of life BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine. 2015-06-08T11:55:32Z 2015-06-08T11:55:32Z 2014-06-20 2015-06-08T11:55:32Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1176-6328 https://hdl.handle.net/2445/65757 649059 25018631 eng Reproducció del document publicat a: http://dx.doi.org/10.2147/NDT.S61409 Neuropsychiatric Disease And Treatment, 2014, vol. 10, p. 1125-1131 http://dx.doi.org/10.2147/NDT.S61409 cc-by-nc (c) Ascher-Svanum, H. et al., 2014 http://creativecommons.org/licenses/by-nc/3.0/es info:eu-repo/semantics/openAccess 7 p. application/pdf Dove Medical Press Articles publicats en revistes (Psicologia Clínica i Psicobiologia)